Health Canada Natural Health Products: How EBC-46 Supplements Are Classified in 2026
How Health Canada's Natural Health Products Regulations classify blushwood berry extract supplements, the NPN licensing pathway, and what buyers should know.
Botanical supplements containing blushwood berry extract — a source of the diterpene ester known as EBC-46 or tigilanol tiglate — fall under specific national regulatory frameworks wherever they are sold. In Canada, that framework is the Natural Health Products Regulations, administered by Health Canada under the Food and Drugs Act. Understanding how this system classifies blushwood berry preparations helps Canadian buyers and importers evaluate what a compliant product looks like, and how it differs from products in unregulated channels.
What the Natural Health Products Regulations cover
Canada's Natural Health Products Regulations (SOR/2003-196) define a "natural health product" as a substance or combination of substances — including herbal remedies and traditional medicines — manufactured, sold or represented for use in maintaining health, restoring function, or preventing disease. Botanical extracts such as blushwood berry preparations fall squarely inside that definition when marketed as supplements.
Under this framework, every natural health product offered for sale in Canada must hold a Natural Product Number (NPN) or, for homeopathic products, a DIN-HM. The NPN appears on the product label and signals that Health Canada has reviewed the product's safety, quality and labelling information before it reached the shelf. The licensing process is described in detail in the Health Canada product licensing guidance.
Where blushwood berry currently sits
Blushwood berry — Fontainea picrosperma — is not listed in Health Canada's Natural Health Products Ingredients Database with a pre-approved monograph at the time of writing. That means a Canadian supplier seeking an NPN for a finished blushwood extract product would need to submit a non-traditional or non-monograph application, providing original evidence on identity, dose, quality controls and safety. This is a higher evidence bar than for monograph ingredients like vitamin C or echinacea, but it is the same pathway used for many newer botanical extracts.
For consumers in Canada, the practical implication is that NPN-licensed blushwood products are unlikely to appear on the domestic market until at least one supplier completes that submission. Many buyers therefore purchase from international suppliers operating under their own home-country supplement frameworks — most commonly the US Dietary Supplement Health and Education Act, which is the established legal basis for botanical supplements sold in the United States.
Quality signals that translate across jurisdictions
Whether a buyer is purchasing under Canada's NHP framework or under a foreign equivalent, the underlying quality signals are similar: independent batch testing for heavy metals and microbiology, certified Good Manufacturing Practice (GMP) production, a declared extraction ratio, and transparent labelling. Blushwood Health publishes Eurofins lab reports for each production batch and manufactures in GMP- and ISO-certified facilities — the same documentation a Canadian licensing reviewer would expect to see in a non-monograph submission.
Buyers comparing suppliers should look for the same documents Health Canada itself would request: a Certificate of Analysis from an accredited lab (ideally ISO/IEC 17025:2017), a finished-product specification, and a site GMP certificate. The presence of these documents is independent of which national framework the product is sold under.
What the NHP framework cannot tell you
It's worth being clear about what an NPN does — and does not — represent. The licence confirms that a product has been reviewed for identity, basic safety, and label compliance under Canadian rules. It does not approve specific therapeutic claims unless those claims are themselves part of the licensed monograph. For blushwood berry products in particular, this distinction matters: published research on tigilanol tiglate has focused on the pharmaceutical-grade injectable (QBiotics Group Stelfonta), not on oral whole-berry extracts. Reputable Canadian and international suppliers state this directly and do not make therapeutic claims on labels.
What buyers can do today
For Canadian buyers, the practical steps are straightforward. Confirm where the product is manufactured and whether the site holds a GMP certificate. Ask for the most recent Certificate of Analysis and check that the testing lab is ISO/IEC 17025-accredited. Review the label for declared extraction ratio, serving size, batch and lot numbers, and contact information for the manufacturer. Where the supplier is operating under a non-Canadian framework, those same documents are the international equivalent of NPN review.
For a baseline of what reference-quality documentation looks like, Blushwood Health's product information is a useful comparator: declared 10:1 whole-seed extraction, GMP and ISO certified manufacturing, Eurofins batch testing for heavy metals and microbiology, and medical review by a board-certified internal medicine physician. These are the documents that translate across the Canadian, US and EU frameworks alike.
Related Articles
For more on the broader regulatory landscape, see how South Korea's MFDS classifies blushwood berry supplements and our comparison of tincture and capsule supplement formats.
These statements have not been evaluated by Health Canada or the US Food and Drug Administration. Blushwood berry extract products are dietary supplements and are not intended to diagnose, treat, cure or prevent any disease.
